FDA Slow Walking a Long-Awaited Abortion Pill Safety Study

The Food and Drug Administration has delayed a promised review of safety data for the abortion drug mifepristone at Commissioner Marty Makary’s request to put it off until after the midterm elections, according to people familiar with the matter.